A Ridgeway, MD
Pulmonary Disease · Sheffield, ALNPI 1326013558
Payments from drug & device makers
Across 353 payments — averaging $1230.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$386K
- Sanofi US Services Inc.$34K
- GSK$7K
- Lexicon Pharmaceuticals, Inc.$5K
- Indivior Inc.$452
- Lilly USA, LLC$286
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,18897%
- Education$1773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $385,620 |
| Sanofi US Services Inc. | 3 | $34,285 |
| GSK | 138 | $6,601 |
| Lexicon Pharmaceuticals, Inc. | 1 | $5,095 |
| Indivior Inc. | 25 | $452 |
| Lilly USA, LLC | 15 | $286 |
| Boehringer Ingelheim | 14 | $249 |
| Jazz Pharmaceuticals Inc. | 10 | $198 |
| Insmed, Inc. | 8 | $166 |
| Merck | 9 | $158 |
| Inspire Medical Systems, Inc. | 2 | $142 |
| Regeneron Healthcare Solutions, Inc. | 7 | $137 |
| Sanofi | 7 | $113 |
| Mylan Specialty L.p. | 7 | $109 |
| Novo Nordisk | 5 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| AbbVie(2 entities) | 5 | $75 |
| Otsuka America Pharmaceutical, Inc. | 5 | $63 |
| Pfizer | 3 | $57 |
| Orexo US, Inc. | 3 | $42 |
| Grifols USA, LLC | 2 | $35 |
| Johnson & Johnson | 3 | $35 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| United Therapeutics Corporation | 1 | $23 |
| 3b Medical, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Gilead | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$129
How this compares
$434,233 in reported general payments places this provider in the 95th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 24 | $485,128 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $70,755 |
| NucalaMepolizumab | 12 | $43,676 |
| XolairOmalizumab | 18 | $20,442 |
| MounjaroTirzepatide | 12 | $14,095 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,216 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $2,648 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,128 |
| Gabapentin | 32 | $874 |
| Methylphenidate Hcl | 30 | $585 |
| Atorvastatin Calcium | 42 | $532 |
| Esomeprazole Magnesium | 14 | $523 |
| Zolpidem Tartrate | 44 | $396 |
| Montelukast Sodium | 29 | $392 |
| Losartan Potassium | 20 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala | $6,601 | $114,431103 claims |
| Lilly USA, LLCMounjaro | $286 | $14,09512 claims |
| AstraZenecaBreztri Aerosphere | $385,620 | $10,21617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Sheffield
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
- Bryan GarciaBirmingham$606K
- Darryle BullardCullman$380K
- Marvin SextonDothan$346K
- Veena AntonyBirmingham$327K
- William SaliskiMontgomery$257K
- Steven RoweBirmingham$252K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.